-
Je něco špatně v tomto záznamu ?
Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis
K. Mori, N. Miura, H. Mostafaei, F. Quhal, RS. Motlagh, I. Lysenko, S. Kimura, S. Egawa, PI. Karakiewicz, SF. Shariat,
Jazyk angličtina Země Japonsko
Typ dokumentu časopisecké články, metaanalýza, systematický přehled
NLK
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2003-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- biologické markery krev MeSH
- C-reaktivní protein analýza MeSH
- cystektomie metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfocyty patologie MeSH
- nádory močového měchýře krev mortalita chirurgie MeSH
- neutrofily patologie MeSH
- počet leukocytů MeSH
- počet trombocytů MeSH
- předoperační období MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
This systematic review and meta-analysis aimed to assess the prognostic value of preoperative hematologic biomarkers in patients with urothelial carcinoma of the bladder treated with radical cystectomy. PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in September 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared cancer-specific survival in patients with urothelial carcinoma of the bladder with and without pretreatment laboratoryabnormalities. Formal meta-analyses were performed for this outcome. The systematic review identified 36 studies with 23,632 patients, of these, 32 studies with 22,224 patients were eligible for the meta-analysis. Several preoperative hematologic biomarkers were significantly associated with cancer-specific survival as follows: neutrophil - lymphocyte ratio (pooled hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 1.11-1.29), hemoglobin (pooled HR: 0.87, 95% CI 0.82-0.94), C-reactive protein (pooled HR: 1.44, 95% CI 1.26-1.66), De Ritis ratio (pooled HR: 2.18, 95% CI 1.37-3.48), white blood cell count (pooled HR: 1.05, 95% CI 1.02-1.07), and albumin-globulin ratio (pooled HR: 0.26, 95% CI 0.14-0.48). Several pretreatment laboratory abnormalities in patients with urothelial carcinoma of the bladder were associated with cancer-specific mortality. Therefore, it might be useful to incorporate such hematologic biomarkers into prognostic tools for urothelial carcinoma of the bladder. However, given the study limitations including heterogeneity and retrospective nature of the primary data, the conclusions should be interpreted with caution.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Urology Medical University of Vienna Währinger Gürtel 18 20 1090 Vienna Austria
Department of Urology The Jikei University School of Medicine Tokyo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027968
- 003
- CZ-PrNML
- 005
- 20210114152717.0
- 007
- ta
- 008
- 210105s2020 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10147-020-01690-1 $2 doi
- 035 __
- $a (PubMed)32451768
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- 245 10
- $a Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis / $c K. Mori, N. Miura, H. Mostafaei, F. Quhal, RS. Motlagh, I. Lysenko, S. Kimura, S. Egawa, PI. Karakiewicz, SF. Shariat,
- 520 9_
- $a This systematic review and meta-analysis aimed to assess the prognostic value of preoperative hematologic biomarkers in patients with urothelial carcinoma of the bladder treated with radical cystectomy. PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in September 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared cancer-specific survival in patients with urothelial carcinoma of the bladder with and without pretreatment laboratoryabnormalities. Formal meta-analyses were performed for this outcome. The systematic review identified 36 studies with 23,632 patients, of these, 32 studies with 22,224 patients were eligible for the meta-analysis. Several preoperative hematologic biomarkers were significantly associated with cancer-specific survival as follows: neutrophil - lymphocyte ratio (pooled hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 1.11-1.29), hemoglobin (pooled HR: 0.87, 95% CI 0.82-0.94), C-reactive protein (pooled HR: 1.44, 95% CI 1.26-1.66), De Ritis ratio (pooled HR: 2.18, 95% CI 1.37-3.48), white blood cell count (pooled HR: 1.05, 95% CI 1.02-1.07), and albumin-globulin ratio (pooled HR: 0.26, 95% CI 0.14-0.48). Several pretreatment laboratory abnormalities in patients with urothelial carcinoma of the bladder were associated with cancer-specific mortality. Therefore, it might be useful to incorporate such hematologic biomarkers into prognostic tools for urothelial carcinoma of the bladder. However, given the study limitations including heterogeneity and retrospective nature of the primary data, the conclusions should be interpreted with caution.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a cystektomie $x metody $7 D015653
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počet leukocytů $7 D007958
- 650 _2
- $a lymfocyty $x patologie $7 D008214
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neutrofily $x patologie $7 D009504
- 650 _2
- $a počet trombocytů $7 D010976
- 650 _2
- $a předoperační období $7 D057234
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a nádory močového měchýře $x krev $x mortalita $x chirurgie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan.
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
- 700 1_
- $a Motlagh, Reza Sari $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- 700 1_
- $a Lysenko, Ivan $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- 700 1_
- $a Kimura, Shoji $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- 700 1_
- $a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduriwien.ac.at. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. shahrokh.shariat@meduriwien.ac.at. Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduriwien.ac.at. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduriwien.ac.at. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduriwien.ac.at. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduriwien.ac.at. Department of Urology, University of Jordan, Amman, Jordan. shahrokh.shariat@meduriwien.ac.at. European Association of Urology Research Foundation, Arnhem, The Netherlands. shahrokh.shariat@meduriwien.ac.at.
- 773 0_
- $w MED00005747 $t International journal of clinical oncology $x 1437-7772 $g Roč. 25, č. 8 (2020), s. 1459-1474
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32451768 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152714 $b ABA008
- 999 __
- $a ok $b bmc $g 1608303 $s 1119148
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 25 $c 8 $d 1459-1474 $e 20200526 $i 1437-7772 $m International journal of clinical oncology $n Int J Clin Oncol $x MED00005747
- LZP __
- $a Pubmed-20210105
